share_log

Sonnet BioTherapeutics Announces Progress In Phase 1 Dose-Escalation Trials O SON-1010

Benzinga Real-time News ·  Sep 21, 2022 08:04
  • The SB101 and SB102 studies have together dosed 19 subjects to date
  • This early review of safety sets the stage for further dose escalation
  • Additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment